Outlook Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended December 31, 2022. Outlook Therapeutics is a clinical-stage biopharmaceutical company developing ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation for retinal diseases. The company reported no product sales revenue; gross margin is not applicable.
Financial performance and liquidity
- Net loss: $18.7 million, versus $14.5 million in the prior-year quarter, a $4.2 million increase. Basic and diluted loss per share remained $0.08; weighted-average shares increased to 227.4 million from 188.2 million.
- Operating expenses: Research and development was $9.9 million, essentially flat year over year. General and administrative expense rose to $5.8 million from $3.3 million, primarily reflecting pre-launch professional fees and higher compensation. Operating loss increased to $15.7 million from $13.1 million.
- Cash flow: Operations used $8.9 million, compared with $11.0 million in the prior-year quarter. Financing provided $43.8 million, versus $66.7 million. Cash increased $34.9 million during the quarter to $52.3 million.
- Balance sheet: Cash was $52.3 million at December 31, up from $17.4 million at September 30, 2022, but below $70.2 million at December 31, 2021. Current assets were $61.7 million and current liabilities $15.1 million.
- Debt: Long-term debt was $31.8 million at quarter end. The December 2022 unsecured convertible note bears 9.5% interest and matures January 1, 2024. Interest expense rose to $2.4 million from $0.4 million; the quarter also included a $0.6 million loss on extinguishment of the prior note.
- Equity financing: A December registered direct offering generated $23.5 million net, and ATM sales generated approximately $1.1 million net. Common shares outstanding increased to 256.7 million from 227.3 million at September 30, 2022.
Changes and unusual items
- Net loss worsened by 29% year over year, while operating cash use declined. The company attributed higher G&A to pre-commercial launch preparations and increased staffing.
- ONS-5010 development costs increased by $2.2 million, offset in reported R&D expense by a $2.3 million refund of BLA submission fees.
- The company repaid and cancelled its November 2021 note using proceeds from the December 2022 note. The refinancing included a prepayment fee and the new note has conversion, cash-payment, and default provisions.
Outlook, risks and contingencies
- The FDA accepted the ONS-5010 BLA for filing and set an August 29, 2023 review goal date. The EMA validated the MAA, with a decision expected in early 2024. These are anticipated dates, not guaranteed outcomes.
- Management said existing cash was expected to fund operations through the anticipated FDA decision and into the fourth calendar quarter of 2023. The filing nevertheless states there is substantial doubt about the company’s ability to continue as a going concern; additional financing is needed and there is no assurance it will be obtained.
- Potential funding sources include ATM sales, equity or debt issuance, licensing, partnerships, and marketing arrangements. Failure to secure funding could force reductions, delays, discontinued programs, asset sales, or bankruptcy proceedings.
- The note has a January 2024 maturity, a 7.5% fee on cash payments, and potential balance increases and 22% default interest after specified events. A February 10, 2023 amendment requires cash settlement of a lender conversion notice if the conversion price falls below $0.1756 per share.
- Key risks include regulatory approval, manufacturing and vendor reliance, commercialization and market acceptance, competition, and access to capital. The company reported no material changes to previously disclosed risk factors, no material pending legal proceedings, and effective disclosure controls.
Important facts for investors to verify
- Progress toward the FDA’s August 29, 2023 BLA decision and the EMA’s expected early-2024 decision.
- Actual cash burn and runway relative to management’s estimate, and the timing and terms of additional financing.
- The full economic and dilution effects of the convertible note, including conversion-price adjustments, cash repayment obligations, and default provisions.
- Commercial manufacturing readiness, launch costs, and whether ONS-5010 can gain approval and market acceptance.